Skip to main navigation

Patients & Families
Healthcare Providers
Investors & Media

Our Science
Our Pipeline
Our Company
Our Partnerships
Life at C4T

Our Science
Our Pipeline
- Overview
- Cemsidomide
- CFT8634
- CFT8919
Our Partnerships
Who We Are
Life at C4T

Patients & Families
Healthcare Providers
Investors & Media

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Email Alerts
Contact IR
FAQs

Overview

Featured Menu

Our Corporate Presentation
Our Latest 10-K
Our Scientific Publications
Sign up for email alerts

Press Releases

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Jun 11, 2026

C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

View All News

View all press releases

Upcoming Events

More events are coming soon.

Past Events

Educational KOL Webinar on the Evolving Multiple Myeloma Treatment Landscape, the Role of IKZF1/3 Degradation and Cemsidomide’s Profile

Jun 18, 2026 9:00 AM EDT

Supporting Materials

Educational KOL Webinar: The Role of IZKF1/3 Degradation in MM 1.2 MB

Jefferies Global Healthcare Conference

Jun 4, 2026 9:20 AM EDT

TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026 2:30 PM EDT

View all events

View all of our past events

Change

Volume

52 Week High

52 Week Low

Jun 18, 2026 5:24 PM EDT

Image Description

617-231-0700
info@c4therapeutics.com

490 Arsenal Way, Suite 120
Watertown, MA 02472

© 2026 C4 Therapeutics, Inc., Inc.

Privacy Policy
Terms of Use Agreement

You are now leaving c4therapeutics.com

You are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.

No, I want to stay Yes, I want to Proceed to the Other Site

You are now leaving c4therapeutics.com

You are about to leave C4 Therapeutics, Inc. (C4T)'s website. This link will take you to an independent website that C4T does not control and to which our Privacy Policy does not apply. C4T is not responsible for the privacy practices or content of any third party websites. We encourage you to read the applicable privacy policies and terms of use of such websites prior to using them.

No, I want to stay Yes, I want to Proceed to the Other Site